Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
The company is focused on the development of novel treatments for RNA viruses
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
The platform’s technology works as a compression algorithm for molecular testing
The fund aims at investing in companies that extends human healthspan
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
The company has has 10 existing labs in India
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
